CN111518157B - Triptolide derivative and preparation method and application thereof - Google Patents
Triptolide derivative and preparation method and application thereof Download PDFInfo
- Publication number
- CN111518157B CN111518157B CN202010529052.3A CN202010529052A CN111518157B CN 111518157 B CN111518157 B CN 111518157B CN 202010529052 A CN202010529052 A CN 202010529052A CN 111518157 B CN111518157 B CN 111518157B
- Authority
- CN
- China
- Prior art keywords
- triptolide
- reaction
- derivative
- triptolide derivative
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- DFBIRQPKNDILPW-CIVMWXNOSA-N Triptolide Chemical class O=C1OCC([C@@H]2C3)=C1CC[C@]2(C)[C@]12O[C@H]1[C@@H]1O[C@]1(C(C)C)[C@@H](O)[C@]21[C@H]3O1 DFBIRQPKNDILPW-CIVMWXNOSA-N 0.000 title claims description 59
- 238000002360 preparation method Methods 0.000 title claims description 11
- 150000001875 compounds Chemical class 0.000 claims description 45
- 238000000034 method Methods 0.000 claims description 26
- 239000003814 drug Substances 0.000 claims description 25
- YKUJZZHGTWVWHA-UHFFFAOYSA-N triptolide Natural products COC12CC3OC3(C(C)C)C(O)C14OC4CC5C6=C(CCC25C)C(=O)OC6 YKUJZZHGTWVWHA-UHFFFAOYSA-N 0.000 claims description 25
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 24
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 claims description 18
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 18
- 238000006243 chemical reaction Methods 0.000 claims description 17
- 201000007270 liver cancer Diseases 0.000 claims description 13
- 208000014018 liver neoplasm Diseases 0.000 claims description 13
- 239000008194 pharmaceutical composition Substances 0.000 claims description 13
- 238000005886 esterification reaction Methods 0.000 claims description 11
- 206010006187 Breast cancer Diseases 0.000 claims description 10
- 208000026310 Breast neoplasm Diseases 0.000 claims description 10
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 claims description 10
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Substances CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 claims description 9
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 claims description 9
- 230000000259 anti-tumor effect Effects 0.000 claims description 9
- 239000003937 drug carrier Substances 0.000 claims description 9
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 claims description 8
- 206010028980 Neoplasm Diseases 0.000 claims description 6
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims description 6
- 150000003839 salts Chemical class 0.000 claims description 6
- 239000002904 solvent Substances 0.000 claims description 6
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 4
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 4
- 238000010438 heat treatment Methods 0.000 claims description 4
- 230000008569 process Effects 0.000 claims description 4
- 238000010992 reflux Methods 0.000 claims description 4
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 claims description 3
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 claims description 2
- 239000002671 adjuvant Substances 0.000 claims description 2
- 239000003054 catalyst Substances 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- 238000009833 condensation Methods 0.000 claims description 2
- 230000005494 condensation Effects 0.000 claims description 2
- 238000005755 formation reaction Methods 0.000 claims description 2
- 239000002994 raw material Substances 0.000 claims description 2
- 229960000549 4-dimethylaminophenol Drugs 0.000 claims 2
- 210000004027 cell Anatomy 0.000 description 45
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 40
- 229940079593 drug Drugs 0.000 description 21
- 210000004881 tumor cell Anatomy 0.000 description 18
- 239000000543 intermediate Substances 0.000 description 17
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 13
- 239000000243 solution Substances 0.000 description 13
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 10
- 238000005160 1H NMR spectroscopy Methods 0.000 description 10
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 10
- 239000006285 cell suspension Substances 0.000 description 10
- 230000000694 effects Effects 0.000 description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
- 239000001963 growth medium Substances 0.000 description 9
- 239000002609 medium Substances 0.000 description 9
- 239000012980 RPMI-1640 medium Substances 0.000 description 8
- 230000002401 inhibitory effect Effects 0.000 description 8
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 239000002246 antineoplastic agent Substances 0.000 description 6
- 229910002092 carbon dioxide Inorganic materials 0.000 description 6
- 210000003470 mitochondria Anatomy 0.000 description 6
- 239000000825 pharmaceutical preparation Substances 0.000 description 6
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 5
- 238000004128 high performance liquid chromatography Methods 0.000 description 5
- 238000002114 high-resolution electrospray ionisation mass spectrometry Methods 0.000 description 5
- 210000005229 liver cell Anatomy 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- 230000003595 spectral effect Effects 0.000 description 5
- 230000008685 targeting Effects 0.000 description 5
- 231100000419 toxicity Toxicity 0.000 description 5
- 230000001988 toxicity Effects 0.000 description 5
- 206010067484 Adverse reaction Diseases 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- 230000006838 adverse reaction Effects 0.000 description 4
- 229940041181 antineoplastic drug Drugs 0.000 description 4
- 230000009286 beneficial effect Effects 0.000 description 4
- 238000012258 culturing Methods 0.000 description 4
- 230000029087 digestion Effects 0.000 description 4
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 230000002438 mitochondrial effect Effects 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 239000002953 phosphate buffered saline Substances 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 235000002639 sodium chloride Nutrition 0.000 description 4
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 231100000331 toxic Toxicity 0.000 description 4
- 230000002588 toxic effect Effects 0.000 description 4
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 3
- MWWSFMDVAYGXBV-RUELKSSGSA-N Doxorubicin hydrochloride Chemical compound Cl.O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 MWWSFMDVAYGXBV-RUELKSSGSA-N 0.000 description 3
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 229960002918 doxorubicin hydrochloride Drugs 0.000 description 3
- 230000000857 drug effect Effects 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 239000012894 fetal calf serum Substances 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000008297 liquid dosage form Substances 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 235000019198 oils Nutrition 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 239000008354 sodium chloride injection Substances 0.000 description 3
- 239000000600 sorbitol Substances 0.000 description 3
- 235000010356 sorbitol Nutrition 0.000 description 3
- 239000007858 starting material Substances 0.000 description 3
- 239000006188 syrup Substances 0.000 description 3
- 235000020357 syrup Nutrition 0.000 description 3
- NRBJWZSFNGZBFQ-UHFFFAOYSA-N 1-cyclopropyl-6-fluoro-4-oxo-7-piperazin-1-ylquinoline-3-carboxylic acid;2-hydroxypropanoic acid Chemical compound CC(O)C(O)=O.C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 NRBJWZSFNGZBFQ-UHFFFAOYSA-N 0.000 description 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 108010019160 Pancreatin Proteins 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- CEGOLXSVJUTHNZ-UHFFFAOYSA-K aluminium tristearate Chemical compound [Al+3].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CEGOLXSVJUTHNZ-UHFFFAOYSA-K 0.000 description 2
- 230000003698 anagen phase Effects 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 229960004055 ciprofloxacin lactate Drugs 0.000 description 2
- -1 cyclic diterpenoid compound Chemical class 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000007884 disintegrant Substances 0.000 description 2
- 238000012377 drug delivery Methods 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 235000010445 lecithin Nutrition 0.000 description 2
- 239000000787 lecithin Substances 0.000 description 2
- 229940067606 lecithin Drugs 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 210000001700 mitochondrial membrane Anatomy 0.000 description 2
- 229940055695 pancreatin Drugs 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 229960005322 streptomycin Drugs 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical class OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 description 1
- GGPJJOKKXXPKDX-UHFFFAOYSA-N 1-cyclopropyl-6-fluoro-4-oxo-7-piperazin-1-ylquinoline-3-carboxylic acid;sodium Chemical compound [Na].C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 GGPJJOKKXXPKDX-UHFFFAOYSA-N 0.000 description 1
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 description 1
- WNXNUPJZWYOKMW-UHFFFAOYSA-N 5-bromopentanoic acid Chemical compound OC(=O)CCCCBr WNXNUPJZWYOKMW-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 235000019489 Almond oil Nutrition 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 1
- 206010053961 Mitochondrial toxicity Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 102000007327 Protamines Human genes 0.000 description 1
- 108010007568 Protamines Proteins 0.000 description 1
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 241000830536 Tripterygium wilfordii Species 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 239000008168 almond oil Substances 0.000 description 1
- 229940024548 aluminum oxide Drugs 0.000 description 1
- 229940063655 aluminum stearate Drugs 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 230000000719 anti-leukaemic effect Effects 0.000 description 1
- 239000008365 aqueous carrier Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000005907 cancer growth Effects 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- HOPSCVCBEOCPJZ-UHFFFAOYSA-N carboxymethyl(trimethyl)azanium;chloride Chemical compound [Cl-].C[N+](C)(C)CC(O)=O HOPSCVCBEOCPJZ-UHFFFAOYSA-N 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 150000001767 cationic compounds Chemical class 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 229940044683 chemotherapy drug Drugs 0.000 description 1
- 239000008119 colloidal silica Substances 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000012050 conventional carrier Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- GXGAKHNRMVGRPK-UHFFFAOYSA-N dimagnesium;dioxido-bis[[oxido(oxo)silyl]oxy]silane Chemical compound [Mg+2].[Mg+2].[O-][Si](=O)O[Si]([O-])([O-])O[Si]([O-])=O GXGAKHNRMVGRPK-UHFFFAOYSA-N 0.000 description 1
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
- 229910000396 dipotassium phosphate Inorganic materials 0.000 description 1
- 235000019797 dipotassium phosphate Nutrition 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 229940000406 drug candidate Drugs 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000008157 edible vegetable oil Substances 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000469 ethanolic extract Substances 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 239000003777 experimental drug Substances 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 231100000086 high toxicity Toxicity 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 239000008176 lyophilized powder Substances 0.000 description 1
- 239000000391 magnesium silicate Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 229910000386 magnesium trisilicate Inorganic materials 0.000 description 1
- 235000019793 magnesium trisilicate Nutrition 0.000 description 1
- 229940099273 magnesium trisilicate Drugs 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 230000004898 mitochondrial function Effects 0.000 description 1
- 231100000296 mitochondrial toxicity Toxicity 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000012053 oil suspension Substances 0.000 description 1
- 239000007935 oral tablet Substances 0.000 description 1
- TWNQGVIAIRXVLR-UHFFFAOYSA-N oxo(oxoalumanyloxy)alumane Chemical compound O=[Al]O[Al]=O TWNQGVIAIRXVLR-UHFFFAOYSA-N 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 229920000058 polyacrylate Polymers 0.000 description 1
- 235000010241 potassium sorbate Nutrition 0.000 description 1
- 239000004302 potassium sorbate Substances 0.000 description 1
- 229940069338 potassium sorbate Drugs 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical class CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 229950008679 protamine sulfate Drugs 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000002390 rotary evaporation Methods 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 239000007909 solid dosage form Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 239000001593 sorbitan monooleate Substances 0.000 description 1
- 235000011069 sorbitan monooleate Nutrition 0.000 description 1
- 229940035049 sorbitan monooleate Drugs 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000015398 thunder god vine Nutrition 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 150000003751 zinc Chemical class 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J73/00—Steroids in which the cyclopenta[a]hydrophenanthrene skeleton has been modified by substitution of one or two carbon atoms by hetero atoms
- C07J73/001—Steroids in which the cyclopenta[a]hydrophenanthrene skeleton has been modified by substitution of one or two carbon atoms by hetero atoms by one hetero atom
- C07J73/003—Steroids in which the cyclopenta[a]hydrophenanthrene skeleton has been modified by substitution of one or two carbon atoms by hetero atoms by one hetero atom by oxygen as hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明提供一种雷公藤甲素衍生物，其具有式I所示结构：其中，n为4‑10的整数。本发明所述的雷公藤甲素衍生物在保留较好的抗肿瘤活性的同时对肿瘤细胞具有更好的选择性，对正常细胞的毒性降低，以及具有更好的水溶性，有利于药物的体内吸收和发挥药效，减少不良反应，本发明的雷公藤甲素衍生物具有作为抗肿瘤药物的潜力。The present invention provides a triptolide derivative, which has the structure shown in formula I: 
where n is an integer of 4-10. The triptolide derivatives of the present invention have better selectivity to tumor cells while retaining better anti-tumor activity, reduce toxicity to normal cells, and have better water-solubility, which is beneficial to the efficacy of drugs. Absorbing and exerting drug effect in vivo, reducing adverse reactions, the triptolide derivative of the present invention has the potential as an antitumor drug.
Description
Technical Field
The invention relates to the technical field of medicines, in particular to a triptolide derivative and a preparation method and application thereof.
Background
The information in this background section is only for enhancement of understanding of the general background of the invention and is not necessarily to be construed as an admission or any form of suggestion that this information forms the prior art that is already known to a person of ordinary skill in the art.
The great problem of tumor treatment is poor selectivity and high toxicity of chemotherapeutic drugs. Designing a drug based on the difference between tumor cells and normal cells is expected to achieve a certain selectivity of the antitumor drug. Research shows that the mitochondrial membrane potential of tumor cells is far greater than that of normal cells, and with the understanding of mitochondrial function and structure change in tumor cells, the specific targeting of compounds to mitochondria becomes a new field of drug development.
The natural product is a treasure house for finding the compound with the anti-tumor activity. In 1972, Kupchan isolated and identified a cyclic diterpenoid compound, Triptolide, with significant anti-leukemia activity from an ethanol extract of Tripterygium wilfordii for the first time. Research shows that triptolide is an effective antitumor agent and can inhibit the growth of cancer cells in vitro and in vivo, but because triptolide has poor water solubility and a narrow treatment window, serious adverse reaction can be caused, and the cytotoxicity is high, so that the clinical application of the triptolide is severely limited.
Disclosure of Invention
Therefore, the invention aims to provide the triptolide derivative, the preparation method and the application thereof, compared with the triptolide, the triptolide derivative has better selectivity on tumor cells while keeping better antitumor activity, reduces the toxicity on normal cells, has better water solubility, is beneficial to the in-vivo absorption and the drug effect of the drug, and reduces the adverse reaction, and has the potential of being used as an antitumor drug.
Specifically, the technical scheme of the invention is as follows:
in a first aspect of the present invention, there is provided a triptolide derivative, which has a structure represented by formula I:
wherein n is an integer of 4 to 10, preferably 5 to 10.
The compounds of the invention are cationic compounds with oleophilic and hydrophilic amphiphilicity, have improved water solubility compared with triptolide, and can be gathered at the cell mitochondrial site under the push of mitochondrial transmembrane potential. Because the mitochondrial membrane potential of tumor cells is higher than that of normal cells, it can provide a driving force for selective accumulation in the mitochondria of tumor cells, thus having mitochondrial targeting and the compounds of the invention exhibit mitochondrial toxicity which can lead to tumor cell death.
The inventor of the present invention studied the effect of structural change on the antitumor activity and the attenuation of normal cells in the research process of the present invention, and found that, as shown in the following structure, the A, B, C three parts are necessary structures for achieving the antitumor effect and the attenuation of normal cells of the present invention, and n in the B part is an integer of 4 to 10, and particularly, as shown in the following structure, the C part can not only bring about the targeting effect, but also exhibit a very desirable attenuation of normal cells while maintaining a good antitumor effect when it is linked to the A, B (n is an integer of 4 to 10) two parts in the following manner. However, if the value of n in part B is too high, for example, n is 11 or more, the inhibitory effect on breast cancer cells is significantly reduced and the inhibitory activity (in terms of IC) is significantly lowered50Value counting) canThe reduction is about 40 times, the inhibition effect on liver cancer cells is poor, and the liver cancer cells hardly have attenuation effect on normal cells.
In addition, the invention also synthesizes
The results show that the compounds with two structures can show certain activity of inhibiting liver cancer cells, wherein,
when the value of n is an integer of 4-10, the compound can show a cancer inhibition effect equivalent to triptolide, but cannot reduce the toxic effect on normal cells;
in the formula, when n is an integer of 3-10, the compound has a certain inhibitory effect on breast cancer cells, namely IC50The value was about 0.6 to 0.8. mu.M, but the attenuation effect on normal cells was not exhibited.
In a more preferred embodiment of the invention, n is preferably 4, 5, 6, 7, 10, said compound being selected from the following structures:
in a second aspect of the present invention, there is provided a method for preparing the triptolide derivative described in the first aspect, comprising: taking triptolide TP as a starting raw material, carrying out esterification reaction on C-14 beta-OH of triptolide to obtain an intermediate compound, and then carrying out salt forming reaction on the intermediate compound and triphenylphosphine to generate the triptolide derivative shown in the formula I;
wherein n is an integer of 4 to 10.
In some embodiments provided herein, the method is carried out via the following reaction scheme:
wherein n is an integer of 4 to 10;
in some embodiments of the invention, the condensation agent of the esterification reaction is selected from one or more of N, N '-Dicyclohexylcarbodiimide (DCC), N' -Diisopropylcarbodiimide (DIC), 1-ethyl- (3-dimethylaminopropyl) carbodiimide hydrochloride (EDCI), preferably EDCI; the catalyst for the esterification reaction is selected from one or more of 4-Dimethylaminopyridine (DMAP), Triethylamine (TEA) and N, N-Diisopropylethylamine (DIPEA), and is preferably DMAP.
In a further embodiment of the present invention, the esterification reaction is performed by the EDCI/DMAP method, the solvent for the esterification reaction is one or more selected from the group consisting of chloroform, N-dimethylformamide, and dichloromethane, preferably dichloromethane, and the reaction temperature is room temperature.
In some embodiments of the invention, the solvent for the salt-forming reaction is selected from one or more of toluene, N-dimethylformamide, N-butanol and acetonitrile, preferably acetonitrile.
In some embodiments of the invention, the salt formation reaction is carried out under heating reflux conditions at 80-85 ℃.
In some preferred embodiments, the method comprises: taking triptolide as a starting material, and carrying out the reaction in dichloromethane at room temperature by an EDCI/DMAP method
Performing esterification reaction, detecting to obtain yellow clear solution, and separating to obtain intermediate compound
And then carrying out salt-forming reaction with triphenylphosphine in acetonitrile as a solvent under the condition of heating reflux at the temperature of 80-85 ℃, and separating to obtain the compound of the formula X after the detection reaction is finished.
Wherein in the method, triptolide, EDCI, DMAP,
The adding amount ratio of dichloromethane is 1mol:4mol:2mol:3mol:55 mL; the adding amount ratio of the intermediate compound, triphenylphosphine and acetonitrile is 1mol: (3-3.1) mol: 120 mL.
It will be appreciated that in the light of the present disclosure, one skilled in the art can further optimize the reaction conditions based on the present disclosure, such as selecting alternative solvents among the more commonly used reagents in the art, such as further scaling up or scaling down the reaction in routine adjustments to achieve higher yields or reduce the production of impurities based on the amounts of materials disclosed herein, and of course, it will be understood that after each reaction, one skilled in the art can select operations to purify the product to further refine the next reaction, and that routine purification methods can be selected either as an option or after routine experimentation.
In a third aspect of the present invention, there is provided a pharmaceutical composition comprising the triptolide derivative as described in the first aspect above.
In a fourth aspect of the present invention, there is provided a pharmaceutical preparation comprising the triptolide derivative of the first aspect and at least one pharmaceutically acceptable carrier or adjuvant.
The "composition" as described herein refers to a pharmaceutical product comprising a therapeutically effective amount of the specified ingredients, as well as any product which results, directly or indirectly, from combination of the specified ingredients in the specified amounts.
The triptolide derivative or the pharmaceutical composition or the pharmaceutical preparation containing the triptolide derivative can be administered in a unit dosage form. The administration dosage form can be liquid dosage form or solid dosage form. The liquid dosage form can be true solution, colloid, microparticle, emulsion, or mixed suspension. Other dosage forms such as tablet, capsule, dripping pill, aerosol, pill, powder, solution, suspension, emulsion, granule, suppository, lyophilized powder for injection, clathrate, etc.
The pharmaceutical composition or pharmaceutical preparation of the present invention may further comprise conventional carriers, including but not limited to: ion exchangers, aluminum oxide, aluminum stearate, lecithin, serum proteins such as human serum albumin, buffer substances (e.g. phosphates, glycerol, sorbitan esters, potassium sorbate, partial glyceride mixtures of saturated vegetable fatty acids, water, salts) or electrolytes, protamine sulfate, disodium hydrogen phosphate, potassium hydrogen phosphate, sodium chloride, zinc salts, colloidal silica, magnesium trisilicate, polyvinylpyrrolidone, cellulosic substances, polyethylene glycol, sodium carboxymethylcellulose, polyacrylates, beeswax, lanolin and the like. The amount of carrier in the pharmaceutical composition or formulation may be from 1% to 98% by weight, usually about 80% by weight. Preservatives, buffers and the like may be present in the carrier as is conventional.
The pharmaceutically acceptable excipients include, but are not limited to, excipients which may be binders, fillers, lubricants, disintegrants, buffers, stabilizers, preservatives, and the like. The auxiliary material refers to a component except for an effective component in the pharmaceutical composition or the pharmaceutical preparation, is nontoxic to a subject, and can stably coexist with a pharmaceutical active component or stably coexist after adopting a proper means.
Oral tablets and capsules may contain binders such as syrup, acacia, sorbitol, tragacanth or polyvinylpyrrolidone; fillers such as lactose, sucrose, corn starch, calcium phosphate, sorbitol, glycine; lubricants such as magnesium stearate, talc, polyethylene glycol, silica; a disintegrant such as potato starch, or an acceptable humectant such as sodium lauryl sulfate may be present. The tablets may be coated by methods known in the art of pharmacy.
The oral liquid can be made into water and oil suspension, solution, emulsion, syrup, or dried product, and supplemented with water or other suitable medium before use. Such liquid preparations may contain conventional additives such as suspending agents, sorbitol, cellulose methyl ether, glucose syrup, gelatin, hydroxyethyl cellulose, carboxymethyl cellulose, aluminium stearate gel, hydrogenated edible fats and oils, emulsifying agents, such as lecithin, sorbitan monooleate, gum arabic; or a non-aqueous carrier (which may comprise an edible oil), such as almond oil, an oil such as glycerol, ethylene glycol, or ethanol; preservatives, e.g. methyl or propyl p-hydroxybenzoates, sorbic acid. Flavoring or coloring agents may be added if desired.
For parenteral administration, liquid dosage forms are generally prepared from the compound and a sterile carrier. The carrier is preferably water. The compound can be dissolved in the carrier or made into suspension solution according to the concentration of the carrier and the drug, and the compound is firstly dissolved in water when made into the solution for injection, filtered and sterilized and then filled into a sealed bottle or ampoule.
In a fifth aspect of the invention, there is provided a mitochondrially targeted pharmaceutical carrier comprising a triptolide derivative as described in the first aspect above.
In the embodiment of the invention, the triptolide derivative can be selectively accumulated in the mitochondria of the tumor cells by utilizing the membrane potential difference of the tumor cells, so that the triptolide derivative has good mitochondrial targeting of the tumor cells.
In a sixth aspect of the invention, there is provided a delivery system comprising a triptolide derivative as described in the first aspect above or a mitochondrially targeted pharmaceutical carrier as described in the fifth aspect above. The triptolide derivative can be used as a drug delivery system or a main component in the drug delivery system due to good targeting property on tumor cell mitochondria, and can selectively deliver more active drugs into the tumor cell mitochondria to realize good tumor treatment effect.
In a seventh aspect of the present invention, there is provided an application of the triptolide derivative of the first aspect, or the pharmaceutical composition of the third aspect, or the pharmaceutical preparation of the fourth aspect, or the mitochondrion-targeted pharmaceutical carrier of the fifth aspect, or the delivery system of the sixth aspect, in preparing an anti-tumor drug.
In an embodiment of the present invention, the tumor is liver cancer or breast cancer.
In the embodiment of the invention, the compound of the invention has better selectivity on tumor cells and lower toxicity on normal cells compared with triptolide while retaining better antitumor activity (the antitumor activity on liver cancer and breast cancer is equivalent to that of triptolide, but is obviously better than that of doxorubicin hydrochloride), wherein the toxicity of the triptolide derivative on normal liver cells is reduced by up to 827 times (by IC) compared with the triptolide50Value calculation), can be reduced by at least 6-20 times, has better selectivity with tumor cells and is safer for normal cells.
Meanwhile, compared with triptolide, the triptolide derivative disclosed by the invention has better water solubility, is beneficial to in vivo absorption and drug effect exertion of a medicament, and reduces adverse reactions.
Also, the present invention provides a method for treating tumors, especially liver cancer and breast cancer, especially liver cancer, comprising administering to a subject a therapeutically effective amount of the triptolide derivative of the first aspect or the pharmaceutical composition of the third aspect or the pharmaceutical formulation of the fourth aspect or the mitochondrially targeted pharmaceutical carrier of the fifth aspect or the delivery system of the sixth aspect; the subject refers to an animal, preferably a mammal, most preferably a human, who has been the object of treatment, observation or experiment. By "therapeutically effective amount" is meant an amount of active compound or pharmaceutical agent, including a compound of the present invention, that elicits the biological or medicinal response in a tissue system, animal or human that is being sought by a researcher, veterinarian, medical doctor or other medical professional, which includes alleviation or partial alleviation of the symptoms of the disease, syndrome, condition or disorder being treated. It will be appreciated that the optimum dosage and interval for administration of the active ingredients of the invention will be determined by the nature and external conditions, such as the form, route and site of administration and the particular mammal being treated, and that such optimum dosage may be determined by conventional techniques. It should also be recognized that the optimal course of treatment, i.e., the daily dosage of the compound over a nominal period of time, may be determined by methods known in the art.
The invention has the following beneficial effects: the triptolide derivative can target tumor cell mitochondria, has equivalent inhibitory activity to tumor cells compared with triptolide, but has better water solubility and selectivity to tumor cells, greatly reduces the toxic effect to normal cells, can effectively inhibit liver cancer cells and breast cancer cells, can be beneficial to the in vivo absorption and the drug effect of drugs due to the improvement of the water solubility, can greatly reduce the adverse reaction of the drugs due to the lower toxic effect to the normal cells, and has the potential of being developed into a new antitumor drug.
Detailed Description
The invention will be further illustrated with reference to the following specific examples. It should be understood that these examples are for illustrative purposes only and are not intended to limit the scope of the present invention. The experimental procedures, in which specific conditions are not noted in the following examples, are generally carried out according to conventional conditions or according to conditions recommended by the manufacturers.
Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art. The reagents or starting materials used in the present invention can be purchased from conventional sources, and unless otherwise specified, the reagents or starting materials used in the present invention can be used in a conventional manner in the art or in accordance with the product specifications. In addition, any methods and materials similar or equivalent to those described herein can be used in the methods of the present invention. The preferred embodiments and materials described herein are intended to be exemplary only.
Example 1Preparation of Compound Mito-TP-1
Triptolide (0.055mmol, 20mg), 5-bromovaleric acid (0.165mmol, 29.9mg), EDCI (0.22mmol, 42.2mg), DMAP (0.11mmol, 13.4mg) were added to 2ml of anhydrous dichloromethane, reacted at room temperature for 8 hours under nitrogen protection, and the reaction progress was checked by TLC to give a yellow clear solution. Extracting with saturated sodium bicarbonate solution for three times, collecting the dichloromethane layer, adding appropriate amount of anhydrous magnesium sulfate, drying for 20 min, vacuum filtering, rotary evaporating, and concentrating. Separating by silica gel preparative plate method (petroleum ether: ethyl acetate 1: 1) to obtain white solid powder, dissolving intermediate 1(0.0382mmol, 20.0mg) in 3mL acetonitrile, adding triphenylphosphine (0.116mmol, 29.3mg), heating and refluxing at 80 ℃ in oil bath for 48h, detecting that the reaction is basically completed by TLC, and concentrating by rotary evaporation. Separation was carried out by silica gel preparative plate method (dichloromethane: methanol ═ 15: 1) to obtain 13.1mg of white solid, i.e., Mito-TP-1.
The synthetic route is as follows:
spectral data:
intermediate 1:1H NMR(600MHz,CD3OD)δ5.09(s,1H,H-14),4.79(m,2H,H-19),3.97(d,J＝3.2Hz,1H,H-11),3.64(d,J＝3.0Hz,1H,H-12),3.49(m,2H,H-5'),3.49(m,1H,H-7),2.79(m,1H,H-5),2.41(m,2H,H-2'),2.27(m,1H,H-2a),2.27(m,1H,H-6a),2.07(m,1H,H-2b),1.90(m,1H,H-15),1.90(m,1H,H-6b),1.90(m,4H,H-3',H-4'),1.52(m,1H,H-1a),1.35(m,1H,H-1b),1.05(s,3H,H-20),0.96(d,J＝7.0Hz,3H,H-17),0.86(d,J＝6.9Hz,3H,H-16)；13C NMR(150MHz,CD3OD)δ176.24(C-18),174.29(CH 2CO-,C-1'),164.02(C-4),125.69(C-3),72.89(C-14),72.13(C-19),65.04(C-13),64.33(C-9),62.92(C-8),61.28(C-7),56.90(C-11),56.39(C-12),41.60(C-5),36.97(C-10),34.32(C-2'),33.95(C-5'),33.08(C-4'),30.97(C-1),29.79(C-15),24.89(C-6),24.33(C-3'),18.06(C-17),18.06(C-2),17.26(C-16),14.34(C-20).
compound Mito-TP-1:1H NMR(600MHz,CD3OD)δ7.78(m,3H,H-4”),7.65(m,6H,H-2”,H-6”),7.61(m,6H,H-3”,H-5”),4.99(s,1H,H-14),4.77(m,2H,H-19),4.01(d,J＝3.3Hz,1H,H-11),3.68(d,J＝3.1Hz,1H,H-12),3.45(d,J＝5.7Hz,1H,H-7),3.23(m,2H,H-5'),2.70(m,1H,H-5),2.45(m,2H),2.14(m,2H),1.97(m,1H),1.75(m,5H),1.51(m,1H),1.32(m,1H,H-1a),1.20(m,1H,H-1b),0.78(d,J＝7.0Hz,3H,H-20),0.68(d,J＝6.9Hz,3H,H-16),0.62(s,3H,H-20)；13C NMR(150MHz,CD3OD)δ176.15(C-18),174.07(C-1'),163.83(C-4),136.49(d,J＝3.0Hz,C-4”),135.02(d,J＝10.1Hz,C-2”,C-6”),131.72(d,J＝12.9Hz,C-3”,C-5”),125.69(C-3),120.02(d,J＝86.5Hz,C-1”),72.91(C-14),72.11(C-19),65.00(C-13),64.24(C-9),63.10(C-8),61.35(C-7),57.04(C-11),56.25(C-12),41.49(C-5),36.89(C-10),34.18(C-2'),30.93(C-1),29.77(C-15),26.77(d,J＝17.6Hz,C-4'),24.30(C-6),22.98(d,J＝4.2Hz,C-3'),22.58(d,J＝51.8Hz,C-5'),18.07(C-17),18.00(C-2),17.26(C-16),14.46(C-20).HPLC purity:99％.HR-ESI-MS m/z 705.2981(C43H46O7P+[M-Br]+calculations 705.2976)
Example 2Preparation of Compound Mito-TP-2
Intermediate 2 and compound Mito-TP-2 were prepared according to the procedure of example 1, starting from the following synthetic route.
The synthetic route is as follows:
spectral data:
intermediate 2:1H NMR(600MHz,CD3OD)δ5.08(s,1H,H-14),4.80(m,2H,H-19),3.96(d,J＝3.2Hz,1H,H-11),3.63(d,J＝3.1Hz,1H,H-12),3.48(m,2H,H-6'),3.48(m,1H,H-7),2.78(m,1H,H-5),2.48(m,2H,H-2'),2.27(m,1H,H-2a),2.27(m,1H,H-6a),2.06(m,1H,H-2b),1.85(m,1H,H-15),1.85(m,1H,H-6b),1.85(m,2H,H-5'),1.67(m,2H,H-3'),1.50(m,2H,H-4'),1.50(m,1H,H-1a),1.33(m,1H,H-1b),1.04(s,3H,H-20),0.95(d,J＝7.0Hz,3H,H-17),0.85(d,J＝6.9Hz,3H,H-16)；13C NMR(150MHz,CD3OD)δ176.18(C-18),174.53(C-1'),163.98(C-4),125.66(C-3),72.77(C-14),72.12(C-19),65.03(C-13),64.35(C-9),62.85(C-8),61.24(C-7),56.86(C-11),56.35(C-12),41.59(C-5),36.96(C-10),35.10(C-2'),34.29(C-6'),33.83(C-5'),30.96(C-1),29.73(C-15),28.66(C-4'),25.40(C-3'),24.32(C-6),18.09(C-17),18.05(C-2),17.28(C-16),14.37(C-20).
compound Mito-TP-2:1H NMR(600MHz,CD3OD)δ7.90(m,3H,H-4”),7.86(m,6H,H-2”,H-6”),7.77(m,6H,H-3”,H-5”),5.06(s,1H,H-14),4.79(m,2H,H-19),3.95(d,J＝3.2Hz,1H,H-11),3.61(d,J＝2.5Hz,1H,H-12),3.46(m,1H,H-7),3.42(m,2H,H-6'),2.76(d,J＝13.2Hz,1H,H-5),2.37(m,2H,H-2'),2.25(m,1H,H-2a),2.25(m,1H,H-6a),2.00(s,1H,H-2b),1.82(m,1H,H-15),1.82(m,1H,H-6b),1.74(m,6H,H-3',H-4',H-5'),1.30(m,2H,H-1),0.93(d,J＝7.0Hz,3H,H-17),0.90(s,3H,H-20),0.84(d,J＝6.9Hz,3H,H-16)；13C NMR(150MHz,CD3OD)δ176.19(C-18),174.26(C-1'),163.95(C-4),136.48(d,J＝3.6Hz,C-4”),135.02(d,J＝10.5Hz,C-2”,C-6”),131.72(d,J＝12.9Hz,C-3”,C-5”),125.63(C-3),120.08(d,J＝86.6Hz,C-1”),72.84(C-14),72.14(C-19),65.12(C-13),64.30(C-9),62.98(C-8),61.29(C-7),57.05(C-11),56.25(C-12),41.50(C-5),36.91(C-10),34.64(C-2'),30.91(C-1),30.53(d,J＝16.7Hz,C-5'),29.85(C-15),25.16(C-3'),24.29(C-6),23.12(d,J＝5.1Hz,C-4'),22.81(d,J＝51.3Hz,C-6'),18.11(C-17),18.02(C-2),17.29(C-16),14.50(C-20).HPLC purity:98％.HR-ESI-MS m/z 719.3122(C44H48O7P+[M-Br]+calculations 719.3132)
Example 3Preparation of Compound Mito-TP-3
Intermediate 3 and compound Mito-TP-3 were prepared according to the procedure of example 1, starting from the following synthetic route.
The synthetic route is as follows:
spectral data:
intermediate 3:1H NMR(600MHz,CD3OD)δ5.08(s,1H,H-14),4.80(m,2H,H-19),3.96(d,J＝3.1Hz,1H,H-11),3.63(d,J＝2.5Hz,1H,H-12),3.46(m,2H,H-7'),3.46(m,1H,H-7),2.78(m,1H,H-5),2.45(m,2H,H-2'),2.27(m,1H,H-2a),2.27(m,1H,H-6a),2.06(m,1H,H-2b),1.85(m,1H,H-15),1.85(m,1H,H-6b),1.85(m,2H,H-6'),1.67(m,2H,H-3'),1.50(m,2H,H-5'),1.50(m,2H,H-4'),1.50(m,1H,H-1a),1.33(m,1H,H-1b),1.04(s,3H,H-20),0.95(d,J＝7.0Hz,3H,H-17),0.85(d,J＝6.9Hz,3H,H-16)；13C NMR(150MHz,CD3OD)δ176.24(C-18),174.73(C-1'),164.03(C-4),125.68(C-3),72.78(C-14),72.13(C-19),65.04(C-13),64.36(C-9),62.83(C-8),61.26(C-7),56.85(C-11),56.39(C-12),41.61(C-5),36.98(C-10),35.22(C-2'),34.42(C-7'),34.00(C-6'),30.97(C-1),29.78(C-15),29.21(C-4'),29.02(C-5'),26.08(C-3'),24.35(C-6),18.07(C-17),18.07(C-2),17.26(C-16),14.36(C-20).
compound Mito-TP-3:1H NMR(600MHz,CD3OD)δ7.89(m,3H,H-4”),7.85(m,6H,H-2”,H-6”),7.76(m,6H,H-3”,H-5”),5.06(m,1H,H-14),4.78(m,2H,H-19),3.93(d,J＝3.2Hz,1H,H-11),3.60(d,J＝2.4Hz,1H,H-12),3.45(d,J＝5.6Hz,1H,H-7),3.40(m,2H,H-7'),2.76(m,1H,H-5),2.39(m,2H,H-2'),2.24(m,1H,H-2a),2.24(m,1H,H-6a),2.00(m,1H,H-2b),1.81(m,1H,H-15),1.81(m,1H,H-6b),1.69(m,6H,H-3',H-4',H-6'),1.45(m,2H,H-5'),1.45(m,1H,H-1a),1.31(m,1H,H-1b),0.93(d,J＝7.0Hz,3H,H-17),0.88(s,3H,H-20),0.83(d,J＝6.9Hz,3H,H-16)；13C NMR(150MHz,CD3OD)δ176.18(C-18),174.60(C-1'),163.93(C-4),136.47(d,J＝3.6Hz,C-4”),135.00(d,J＝10.2Hz,C-2”,C-6”),131.71(d,J＝13.2Hz,C-3”,C-5”),125.68(C-3),120.11(d,J＝86.2Hz,C-1”),72.77(C-14),72.11(C-19),65.01(C-13),64.29(C-9),62.84(C-8),61.36(C-7),56.91(C-11),56.32(C-12),41.48(C-5),36.91(C-10),35.10(C-2'),31.33(d,J＝16.4Hz,C-6'),30.85(C-1),29.83(C-15),29.05(C-4'),25.83(C-3'),24.33(C-6),23.41(d,J＝4.8Hz,C-5'),22.74(d,J＝50.8Hz,C-7'),18.09(C-17),18.05(C-2),17.26(C-16),14.40(C-20).HPLC purity:94％.HR-ESI-MS m/z733.3292(C45H50O7P+[M-Br]+calculations 733.3289)
Example 4Preparation of Compound Mito-TP-4
Intermediate 4 and compound Mito-TP-4 were prepared according to the procedure of example 1, starting from the following synthetic route.
The synthetic route is as follows:
spectral data:
intermediate 4:1H NMR(600MHz,CD3OD)δ5.07(s,1H,H-14),4.79(m,2H,H-19),3.96(d,J＝3.2Hz,1H,H-11),3.62(m,1H,H-12),3.45(m,2H,H-8'),3.45(m,1H,H-7),2.78(m,1H,H-5),2.39(m,2H,H-2'),2.27(m,1H,H-2a),2.27(m,1H,H-6a),2.08(m,1H,H-2b),1.87(m,1H,H-15),1.87(m,1H,H-6b),1.87(m,2H,H-7'),1.67(m,2H,H-3'),1.47(m,2H,H-6'),1.47(m,2H,H-4'),1.47(m,1H,H-1a),1.36(m,2H,H-5'),1.36(m,1H,H-1b),1.04(s,3H,H-20),0.95(d,J＝7.0Hz,3H,H-17),0.85(d,J＝6.9Hz,3H,H-16)；13C NMR(150MHz,CD3OD)δ176.22(C-18),174.79(C-1'),164.04(C-4),125.68(C-3),72.75(C-14),72.13(C-19),65.04(C-13),64.36(C-9),62.80(C-8),61.24(C-7),56.83(C-11),56.39(C-12),41.61(C-5),36.98(C-10),35.28(C-2'),34.56(C-8'),34.09(C-7'),30.97(C-1),29.92(C-4'),29.77(C-5'),29.64(C-6'),29.18(C-15),26.17(C-3'),24.36(C-6),18.07(C-17),18.06(C-2),17.27(C-16),14.37(C-20).
compound Mito-TP-4:1H NMR(600MHz,CD3OD)δ7.89(m,3H,H-4”),7.80(m,6H,H-2”,H-6”),7.75(m,6H,H-3”,H-5”),5.06(s,1H,H-14),4.78(m,2H,H-19),3.94(d,J＝3.2Hz,1H,H-11),3.61(d,J＝2.3Hz,1H,H-12),3.45(d,J＝5.7Hz,1H,H-7),3.39(m,2H,H-8'),2.77(m,1H,H-5),2.37(m,2H,H-2'),2.25(m,1H,H-2a),2.25(m,1H,H-6a),2.03(m,1H,H-2b),1.82(m,1H,H-15),1.82(m,1H,H-6b),1.64(m,6H,H-3',H-4',H-7'),1.39(m,4H,H-5',H-6'),1.39(m,2H,H-1),0.96(s,3H,H-20),0.93(d,J＝7.0Hz,3H,H-17),0.83(d,J＝6.9Hz,3H,H-16)；13C NMR(150MHz,CD3OD)δ176.20(C-18),174.67(C-1'),163.99(C-4),136.46(d,J＝3.6Hz,C-4”),134.98(d,J＝10.4Hz,C-2”,C-6”),131.69(d,J＝12.4Hz,C-3”,C-5”),125.68(C-3),120.15(d,J＝86.2Hz,C-1”),72.76(C-14),72.12(C-19),65.03(C-13),64.32(C-9),62.78(C-8),61.30(C-7),56.87(C-11),56.33(C-12),41.53(C-5),36.95(C-10),35.21(C-2'),31.52(d,J＝16.5Hz,C-7'),30.89(C-1),29.79(C-15),29.62(C-5'),29.56(C-4'),26.01(C-3'),24.35(C-6),23.54(d,J＝5.0Hz,C-6'),22.76(d,J＝50.8Hz,C-8'),18.09(C-17),18.06(C-2),17.26(C-16),14.40(C-20).HPLC purity:96％.HR-ESI-MS m/z747.3457(C46H52O7P+[M-Br]+calculations 747.3445)
Example 5Preparation of Compound Mito-TP-5
Intermediate 5 and compound Mito-TP-5 were prepared according to the procedure of example 1, starting from the following synthetic route.
The synthetic route is as follows:
spectral data:
intermediate 5:1H NMR(600MHz,CD3OD)δ5.07(s,1H,H-14),4.80(m,2H,H-19),3.96(d,J＝3.2Hz,1H,H-11),3.63(d,J＝3.0Hz,1H,H-12),3.45(m,2H,H-11'),3.45(m,1H,H-7),2.78(m,1H,H-5),2.39(m,2H,H-2'),2.26(m,1H,H-2a),2.26(m,1H,H-6a),2.08(m,1H,H-2b),1.87(m,1H,H-15),1.87(m,1H,H-6b),1.87(m,2H,H-10'),1.66(m,2H,H-3'),1.51(m,1H,H-1a),1.43(m,2H,H-4'),1.35(m,1H,H-1b),1.35(m,10H,H-5',H-6',H-7',H-8',H-9'),1.04(s,3H,H-20),0.95(d,J＝7.0Hz,3H,H-17),0.85(d,J＝6.9Hz,3H,H-16)；13CNMR(150MHz,CD3OD)δ176.23(C-18),174.86(C-1'),164.04(C-4),125.69(C-3),72.74(C-14),72.14(C-19),65.03(C-13),64.35(C-9),62.77(C-8),61.24(C-7),56.82(C-11),56.39(C-12),41.61(C-5),36.98(C-10),35.36(C-2'),34.63(C-11'),34.15(C-10'),30.97(C-1),30.66(C-6'),30.63(C-7'),30.52(C-5'),30.11(C-4'),29.98(C-8'),29.78(C-9'),29.32(C-15),26.30(C-3'),24.38(C-6),18.08(C-17),18.07(C-2),17.27(C-16),14.38(C-20).
compound Mito-TP-5:1H NMR(600MHz,CD3OD)δ7.80(m,3H,H-4”),7.70(m,6H,H-2”,H-6”),7.65(m,6H,H-3”,H-5”),4.97(s,1H,H-14),4.68(m,2H,H-19),3.84(d,J＝3.2Hz,1H,H-11),3.52(m,1H,H-12),3.35(d,J＝5.7Hz,1H,H-7),3.29(m,2H,H-11'),2.68(m,1H,H-5),2.27(m,2H,H-2'),2.15(m,1H,H-2a),2.15(m,1H,H-6a),1.94(m,1H,H-2b),1.75(m,1H,H-15),1.75(m,1H,H-6b),1.55(m,4H,H-3',H-4'),1.44(m,2H,H-10'),1.37(m,1H,H-1a),1.22(m,10H,H-5',H-6',H-7',H-8',H-9'),1.22(m,1H,H-1b),0.91(s,3H,H-20),0.84(d,J＝7.0Hz,3H,H-17),0.73(d,J＝6.9Hz,3H,H-16)；13C NMR(150MHz,CD3OD)δ176.20(C-18),174.81(C-1'),164.04(C-4),136.46(d,J＝3.6Hz,C-4”),134.96(d,J＝10.3Hz,C-2”,C-6”),131.69(d,J＝13.1Hz,C-3”,C-5”),125.65(C-3),120.16(d,J＝86.3Hz,C-1”),72.72(C-14),72.13(C-19),65.03(C-13),64.33(C-9),62.79(C-8),61.25(C-7),56.83(C-11),56.36(C-12),41.57(C-5),36.96(C-10),35.33(C-2'),31.69(d,J＝16.5Hz,C-10'),30.94(C-1),30.47(C-7'),30.42(C-6'),30.07(C-8'),29.94(C-5'),29.77(C-15),26.25(C-4'),24.35(C-3'),23.63(d,J＝5.0Hz,C-9'),22.74(d,J＝51.1Hz,C-11'),18.09(C-17),18.07(C-2),17.26(C-16),14.36(C-20).HPLC purity:99％.HR-ESI-MS m/z 789.3919(C49H58O7P+[M-Br]+calculations 789.3915)
Example 6Control research on antitumor activity of triptolide and triptolide derivatives
1. Experimental Material
Control drugs: triptolide (TP for short) and doxorubicin hydrochloride (DO for short);
experimental drugs: the intermediates 1, 2, 3, 4, 5, and the compounds Mito-TP-1, Mito-TP-2, Mito-TP-3, Mito-TP-4, and Mito-TP-5, which were prepared in examples 1-5 of the present invention.
Cell culture: l-02 normal liver cell lines, Shanghai Qiaoxin Biotechnology, Inc.; HepG-2 human hepatoma cell line, college of medicine, Shandong university; MCF-7 human Thymus cell line, Shandong university college of medicine; RPMI-1640 culture solution, DMEM culture solution, fetal calf serum, trypsin containing 0.25% EDTA, MTT (tetramethyl azone), DMSO (dimethyl sulfoxide), penicillin-streptomycin solution (100x), 0.5% ciprofloxacin lactate sodium chloride injection and PBS (phosphate buffered saline).
The instrument comprises the following steps: an enzyme-labeling instrument: bio Ted, USA; a liquid transfer device: eppendorf, Germany; ultra-clean biological safety cabinet: thermo Fisher Scientific, usa; a carbon dioxide incubator: thermo Fisher Scientific, usa; and (3) sterilizing the pan: sanyo, japan; and (3) inverting the microscope: olympus, japan; minispin centrifuge: eppendorf, germany.
2. Experimental methods
For human liver cancer cells (HepG-2): placing human liver cancer cell (HepG-2) in DMEM culture solution containing 10% fetal calf serum, 1% streptomycin mixture (100X), 0.5% ciprofloxacin lactate and sodium chloride injection, and placing the cell in DMEM culture solution containing 5% CO2Culturing in an incubator at 37 ℃ until the culture medium is paved on the bottom of a dish (d-60mm culture dish), sucking out the culture medium, washing with 1mL of PBS once, adding 500 mu L of DMEM containing EDTA and pancreatin for digestion for 3min, stopping digestion with 1mL of 10% FBS, transferring to a 1.5mL centrifuge tube, centrifuging at 1000rpm for 4min, discarding the supernatant, and taking 1mL of the culture medium for re-suspension to prepare cell suspension. 10 μ L of the cell suspension was taken and counted using a hemocytometer. Calculating the formula: cell count/ml primary cell suspension (total number of cells in four quadrants/4) dilution of cell suspension multiple 104. Adding 300 μ L of cell suspension into 11mL of DMEM medium containing 10% FBS, and inoculating 100 μ L of cells into 96-well plate at a concentration of (8-10) × 103/ml，5％CO2And cultured overnight in an incubator at 37 ℃. After the cells are attached and grow to the logarithmic growth phase, the drugs are diluted by 2% FBS DMEM medium, the cells are treated by the drugs with different concentrations, meanwhile, a control group (blank control group: 2% FBS DMEM medium added with 0.1% DMSO) is set up, each well is 100 mu L, and the drug action time is 48 h. After the drug action time is over, 1mL of MTT is added into 9mL of serum-free DMEM medium, the DMEM medium containing 2% FBS of the drug is aspirated, 100 mu L of the drug is added into each well, and 5% CO is added into each well2And culturing for 4 hours in an incubator at 37 ℃. After the MTT incubation is finished, the DMEM medium containing MTT is absorbed and removed, 100 mu L DMSO is added into each well, the plate is shaken for 1min, and the absorbance (OD value) is measured at 570nm of an enzyme-labeling instrument.
Human hepatic normal cell L-02: placing normal human liver cells (L-02) in a mixture containing 10% fetal calf serum, 1% streptomycin (100X), and 0.5% lactic acidIn RPMI-1640 culture solution of ciprofloxacin sodium chloride injection, cells are placed in a medium containing 5% CO2Culturing in an incubator at 37 ℃ until the culture medium is paved on the bottom of a dish (d-60mm culture dish), sucking out the culture medium, washing with 1mL PBS once, adding 500 mu L of RPMI-1640 culture medium containing EDTA and pancreatin for digestion for 2min and 1mL of 10% FBS to stop digestion, transferring to a 1.5mL centrifuge tube, centrifuging at 1000rpm for 4min, discarding the supernatant, and taking 1mL of culture medium to resuspend to prepare cell suspension. 10 μ L of the cell suspension was taken and counted using a hemocytometer. Calculating the formula: cell count/ml primary cell suspension (total number of cells in four quadrants/4) dilution of cell suspension multiple 104. Adding 300 μ L of cell suspension into 11mL of RPMI-1640 medium containing 10% FBS, and inoculating cells into 96-well plate at a concentration of (8-10) × 10 (100 μ L/well)3/ml，5％CO2And cultured overnight in an incubator at 37 ℃. After the cells are attached and grow to the logarithmic growth phase, the drug is diluted by 2% FBS RPMI-1640 culture medium, the cells are treated by the drug with different concentrations, and a control group (blank control group: 2% FBS RPMI-1640 culture medium added with 0.1% DMSO) is set up at the same time, each well is 100 muL, and the drug action time is 48 h. After the drug action time is over, 1mL of MTT is added into 9mL of serum-free RPMI-1640 medium, and the RPMI-1640 medium containing 2% FBS is aspirated, wherein each well contains 100 mu L of 5% CO2And culturing for 4 hours in an incubator at 37 ℃. After the incubation of MTT, the medium containing MTT was aspirated, 100. mu.L of DMSO was added to each well, the plate was shaken for 1min, and the absorbance (OD value) was measured at 570nm using a microplate reader.
For human breast tumor cells (MCF-7): the operation steps are the same as those of normal human liver cells (L-02).
All results are in accordance with the formula: lgIC50＝Xm-I*[sigP-(3-Pm-Pn)/4]Calculate the IC50Wherein Xm is the logarithm of the highest concentration of the drug; sigP is the sum of all inhibition rates; lg (highest concentration of drug/concentration of drug adjacent to the highest concentration); pm is the maximum killing rate; pn is the minimum kill rate.
3. Results of the experiment
IC of compound Mito-TP-1, compound Mito-TP-2, compound Mito-TP-3, compound Mito-TP-4, compound Mito-TP-5 and triptolide50(μ M) results of the comparison are shown in Table 1.
TABLE 1 triptolide derivatives and triptolide IC50(μ M) comparison
As can be seen from table 1: compared with triptolide, the triptolide derivative prepared by the invention has equivalent inhibitory activity on liver cancer cells and breast cancer cells, and has better inhibitory activity compared with doxorubicin hydrochloride; the intermediate compounds 1-5 of the triptolide derivative also show inhibitory activity on liver cancer cells and breast cancer cells, but the toxicity of Mito-TP-1-Mito-TP-5 on normal cells is generally reduced compared with triptolide, wherein the toxicity of the compounds Mito-TP-1, Mito-TP-2, Mito-TP-3, Mito-TP-4 and Mito-TP-5 on normal liver cells L-02 is reduced by about 827 times, 16 times, 15 times, 6 times and 20 times respectively, while the intermediate compounds 1-5 do not have obvious attenuation activity and have equivalent toxic effect with the triptolide.
Although the present invention has been described in detail with reference to the foregoing embodiments, it will be apparent to those skilled in the art that changes may be made in the embodiments and/or equivalents thereof without departing from the spirit and scope of the invention. Any modification, equivalent replacement, or improvement made within the spirit and principle of the present invention should be included in the protection scope of the present invention.
Claims (14)
1. A triptolide derivative has a structure shown in formula I:
wherein n is an integer of 4 to 10.
2. The triptolide derivative according to claim 1, wherein the compound is selected from the following structures:
3. a method for preparing the triptolide derivative of claim 1 or 2, comprising: taking triptolide TP as a starting raw material, carrying out esterification reaction on C-14 beta-OH of triptolide to obtain an intermediate compound, and then carrying out salt forming reaction on the intermediate compound and triphenylphosphine to generate the triptolide derivative shown in the formula I;
wherein n is an integer of 4 to 10.
4. The process according to claim 3, characterized in that it is carried out by the following reaction scheme:
wherein n is an integer of 4 to 10.
5. The process of claim 3, wherein the condensation agent for the esterification reaction is selected from one or more of DCC, DIC and EDCI; the catalyst for the esterification reaction is one or more selected from DMAP, TEA and DIPEA.
6. The method according to claim 3, wherein the esterification reaction is performed by EDCI/DMAP method, the solvent of the esterification reaction is one or more selected from chloroform, N-dimethylformamide and dichloromethane, and the reaction temperature is room temperature.
7. The method according to claim 3, wherein the solvent for salt forming reaction is selected from one or more of toluene, N-dimethylformamide, N-butanol and acetonitrile.
8. The process of claim 3, wherein the salt formation reaction is carried out under heating reflux conditions at 80-85 ℃.
9. A pharmaceutical composition comprising the triptolide derivative of claim 1 or 2.
10. A pharmaceutical formulation comprising the triptolide derivative of claim 1 or 2 and at least one pharmaceutically acceptable carrier or adjuvant.
11. A mitochondrially targeted drug carrier comprising the triptolide derivative of claim 1 or 2.
12. A delivery system comprising the triptolide derivative of claim 1 or 2 or the mitochondrially-targeted pharmaceutical carrier of claim 11.
13. Use of the triptolide derivative of claim 1 or 2, or the pharmaceutical composition of claim 9, or the pharmaceutical formulation of claim 10, or the mitochondrially-targeted pharmaceutical carrier of claim 11, or the delivery system of claim 12 for the preparation of an anti-tumor medicament.
14. The use of claim 13, wherein the tumor is liver cancer or breast cancer.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010529052.3A CN111518157B (en) | 2020-06-11 | 2020-06-11 | Triptolide derivative and preparation method and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010529052.3A CN111518157B (en) | 2020-06-11 | 2020-06-11 | Triptolide derivative and preparation method and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN111518157A CN111518157A (en) | 2020-08-11 |
| CN111518157B true CN111518157B (en) | 2021-02-23 |
Family
ID=71911474
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010529052.3A Active CN111518157B (en) | 2020-06-11 | 2020-06-11 | Triptolide derivative and preparation method and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN111518157B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114042043B (en) * | 2021-11-26 | 2023-03-24 | 河南中医药大学 | Tripterygium wilfordii mitochondria targeted liposome and application thereof |
Citations (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014167581A2 (en) * | 2013-04-01 | 2014-10-16 | Laurus Labs Private Limited | An improved process for the preparation of triptolide prodrugs |
| CN105924492A (en) * | 2016-04-28 | 2016-09-07 | 山东大学 | Mitochondrion-targeted antitumor pentacyclic triterpene derivatives, and preparation method and application thereof |
| CN108578708A (en) * | 2018-04-25 | 2018-09-28 | 中国科学院化学研究所 | A kind of double target polypeptide-drug conjugates and preparation method thereof and antitumor application thereof |
| CN109021061A (en) * | 2018-09-29 | 2018-12-18 | 郭可点 | Triptolide targeted prodrug and its preparation method and application |
| CN109081852A (en) * | 2018-07-14 | 2018-12-25 | 福州大学 | A kind of dual-target phthalocyanines anticancer photosensitizer and preparation method thereof |
| CN109942665A (en) * | 2018-04-02 | 2019-06-28 | 欣凯医药化工中间体（上海）有限公司 | Triptolide alcohol derivative and its preparation method and application |
| CN110003304A (en) * | 2019-04-22 | 2019-07-12 | 湖北大学 | A kind of water solubility triptolide derivative and its preparation method and application |
| CN110498829A (en) * | 2018-05-16 | 2019-11-26 | 中国医学科学院药物研究所 | Triptolide derivatives, preparation methods, pharmaceutical compositions and applications thereof |
| CN111040018A (en) * | 2019-12-30 | 2020-04-21 | 广东省中医院（广州中医药大学第二附属医院、广州中医药大学第二临床医学院、广东省中医药科学院） | Triptolide acrylate, preparation method and application thereof |
-
2020
- 2020-06-11 CN CN202010529052.3A patent/CN111518157B/en active Active
Patent Citations (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014167581A2 (en) * | 2013-04-01 | 2014-10-16 | Laurus Labs Private Limited | An improved process for the preparation of triptolide prodrugs |
| CN105924492A (en) * | 2016-04-28 | 2016-09-07 | 山东大学 | Mitochondrion-targeted antitumor pentacyclic triterpene derivatives, and preparation method and application thereof |
| CN109942665A (en) * | 2018-04-02 | 2019-06-28 | 欣凯医药化工中间体（上海）有限公司 | Triptolide alcohol derivative and its preparation method and application |
| CN108578708A (en) * | 2018-04-25 | 2018-09-28 | 中国科学院化学研究所 | A kind of double target polypeptide-drug conjugates and preparation method thereof and antitumor application thereof |
| CN110498829A (en) * | 2018-05-16 | 2019-11-26 | 中国医学科学院药物研究所 | Triptolide derivatives, preparation methods, pharmaceutical compositions and applications thereof |
| CN109081852A (en) * | 2018-07-14 | 2018-12-25 | 福州大学 | A kind of dual-target phthalocyanines anticancer photosensitizer and preparation method thereof |
| CN109021061A (en) * | 2018-09-29 | 2018-12-18 | 郭可点 | Triptolide targeted prodrug and its preparation method and application |
| CN110003304A (en) * | 2019-04-22 | 2019-07-12 | 湖北大学 | A kind of water solubility triptolide derivative and its preparation method and application |
| CN111040018A (en) * | 2019-12-30 | 2020-04-21 | 广东省中医院（广州中医药大学第二附属医院、广州中医药大学第二临床医学院、广东省中医药科学院） | Triptolide acrylate, preparation method and application thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN111518157A (en) | 2020-08-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR20110010753A (en) | Treprostinil Monohydrate | |
| US9623111B2 (en) | Pegylated artesunate derivative, pharmaceutical composition and use thereof | |
| CN108467418A (en) | Epigallo-catechin gallate (EGCG) glycosides derivatives and its application | |
| CN110964078B (en) | Hederagenin compound H-X with anti-lung cancer effect and preparation method and application thereof | |
| CN111333692B (en) | Betulinic acid derivative and preparation method and application thereof | |
| CN111518157B (en) | Triptolide derivative and preparation method and application thereof | |
| WO2020177748A1 (en) | Quaternized modified taxane derivative, and pharmaceutical composition and use thereof | |
| CN102603836A (en) | Schisandrin C simplifier, schisandrin analogue, preparation method and applications thereof | |
| CN110041342B (en) | Selenium-containing compound and application thereof | |
| CN114907438A (en) | A kind of lupin alcohol coupling triphenylphosphine derivative and its preparation and application | |
| CN104513290A (en) | Triptolidenol derivative and application thereof | |
| CN107216283B (en) | A kind of beta-elemene derivatives and its preparation method and application containing dihydropyridine structure | |
| CN110563679B (en) | A sesquiterpene lactone compound and its preparation method and its application in the preparation of a medicine for preventing and treating nasopharyngeal carcinoma | |
| CN1990489B (en) | Use of bohnenkraut ethers compounds and compositions thereof | |
| TW201504213A (en) | Indole compound as squamous cell carcinoma and liver cancer inhibitor and use thereof | |
| EP3398596A1 (en) | Ingenol compounds and use thereof in anti-hiv latency treatment | |
| CN104224796B (en) | Application of oleanane triterpene ester derivative in preparation for anti-neurodegeneration medicine | |
| WO2020038279A1 (en) | Substituted pyrazole compound, and preparation method, pharmaceutical composition, and use thereof | |
| EP2963030B1 (en) | 6,8-substituted naringenin derivative and use thereof | |
| WO2016034126A1 (en) | Anti-tumor compound and medical use thereof | |
| CN102796157B (en) | Caudatin derivative and medicinal composition and application thereof | |
| CN101602787B (en) | Alisol A derivative, medicinal composition, preparation method and application thereof | |
| CN116003469B (en) | Preparation and use methods of pyrimidinyl antiviral compounds | |
| KR100979921B1 (en) | Brown Cloud Mushroom Extract and Lactone Compounds Isolated therefrom and Anti-Obesity Composition Comprising the Same | |
| CN118852283A (en) | Compound for preventing and treating tumors and its preparation method and application |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |